L. Roy Papp & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $315K | Sell |
13,078
-240
| -2% | -$6.28K | 0.03% | 162 |
|
|
2026
Q1 | $374K | Buy |
13,318
+115
| +0.9% | +$3.06K | 0.04% | 144 |
|
|
2025
Q4 | $329K | Sell |
13,203
-2,132
| -14% | -$53.8K | 0.04% | 151 |
|
|
2025
Q3 | $391K | Sell |
15,335
-305
| -2% | -$7.53K | 0.04% | 140 |
|
|
2025
Q2 | $379K | Hold |
15,640
| – | – | 0.05% | 141 |
|
|
2025
Q1 | $396K | Sell |
15,640
-1,332
| -8% | -$34.9K | 0.05% | 137 |
|
|
2024
Q4 | $450K | Sell |
16,972
-782
| -4% | -$21.2K | 0.05% | 132 |
|
|
2024
Q3 | $514K | Sell |
17,754
-258
| -1% | -$7.53K | 0.06% | 124 |
|
|
2024
Q2 | $504K | Buy |
18,012
+1,435
| +9% | +$39.5K | 0.06% | 119 |
|
|
2024
Q1 | $460K | Hold |
16,577
| – | – | 0.05% | 126 |
|
|
2023
Q4 | $477K | Sell |
16,577
-450
| -3% | -$13.6K | 0.06% | 120 |
|
|
2023
Q3 | $565K | Sell |
17,027
-3,328
| -16% | -$118K | 0.08% | 108 |
|
|
2023
Q2 | $747K | Sell |
20,355
-4,800
| -19% | -$187K | 0.1% | 105 |
|
|
2023
Q1 | $1.03M | Hold |
25,155
| – | – | 0.14% | 93 |
|
|
2022
Q4 | $1.29M | Sell |
25,155
-265
| -1% | -$12.7K | 0.18% | 84 |
|
|
2022
Q3 | $1.11M | Buy |
25,420
+275
| +1% | +$13.4K | 0.17% | 85 |
|
|
2022
Q2 | $1.32M | Buy |
25,145
+211
| +0.8% | +$10.8K | 0.19% | 81 |
|
|
2022
Q1 | $1.29M | Sell |
24,934
-169
| -0.7% | -$8.77K | 0.16% | 90 |
|
|
2021
Q4 | $1.48M | Sell |
25,103
-55
| -0.2% | -$2.73K | 0.17% | 86 |
|
|
2021
Q3 | $1.08M | Hold |
25,158
| – | – | 0.14% | 93 |
|
|
2021
Q2 | $985K | Buy |
25,158
+1,100
| +5% | +$42.8K | 0.12% | 96 |
|
|
2021
Q1 | $872K | Buy |
24,058
+1,318
| +6% | +$46.8K | 0.13% | 99 |
|
|
2020
Q4 | $837K | Hold |
22,740
| – | – | 0.1% | 108 |
|
|
2020
Q3 | $792K | Sell |
22,740
-2,386
| -9% | -$83.7K | 0.1% | 104 |
|
|
2020
Q2 | $780K | Hold |
25,126
| – | – | 0.11% | 100 |
|
|
2020
Q1 | $778K | Sell |
25,126
-1,079
| -4% | -$36.8K | 0.14% | 99 |
|
|
2019
Q4 | $974K | Sell |
26,205
-219
| -0.8% | -$7.8K | 0.14% | 94 |
|
|
2019
Q3 | $901K | Buy |
26,424
+843
| +3% | +$30.7K | 0.14% | 98 |
|
|
2019
Q2 | $1.05M | Buy |
25,581
+2,985
| +13% | +$119K | 0.16% | 94 |
|
|
2019
Q1 | $910K | Buy |
22,596
+349
| +2% | +$14K | 0.16% | 85 |
|
|
2018
Q4 | $921K | Sell |
22,247
-134
| -0.6% | -$5.56K | 0.19% | 84 |
|
|
2018
Q3 | $936K | Sell |
22,381
-1,596
| -7% | -$61.4K | 0.17% | 88 |
|
|
2018
Q2 | $825K | Sell |
23,977
-633
| -3% | -$21.6K | 0.16% | 93 |
|
|
2018
Q1 | $829K | Buy |
24,610
+1,486
| +6% | +$51.1K | 0.16% | 96 |
|
|
2017
Q4 | $795K | Hold |
23,124
| – | – | 0.16% | 93 |
|
|
2017
Q3 | $783K | Sell |
23,124
-632
| -3% | -$20.3K | 0.17% | 84 |
|
|
2017
Q2 | $757K | Sell |
23,756
-1,054
| -4% | -$33.2K | 0.16% | 89 |
|
|
2017
Q1 | $805K | Sell |
24,810
-1,680
| -6% | -$53K | 0.18% | 85 |
|
|
2016
Q4 | $816K | Buy |
26,490
+1,469
| +6% | +$44.8K | 0.19% | 88 |
|
|
2016
Q3 | $804K | Sell |
25,021
-632
| -2% | -$21.1K | 0.19% | 87 |
|
|
2016
Q2 | $857K | Sell |
25,653
-112
| -0.4% | -$3.58K | 0.2% | 89 |
|
|
2016
Q1 | $725K | Buy |
25,765
+12,882
| +100% | +$368K | 0.17% | 93 |
|
|
2015
Q4 | $395K | Sell |
12,883
-3,310
| -20% | -$104K | 0.1% | 111 |
|
|
2015
Q3 | $483K | Buy |
16,193
+2,909
| +22% | +$93.3K | 0.12% | 102 |
|
|
2015
Q2 | $423K | Buy |
13,284
+29
| +0.2% | +$945 | 0.1% | 110 |
|
|
2015
Q1 | $438K | Sell |
13,255
-2,103
| -14% | -$66.9K | 0.1% | 111 |
|
|
2014
Q4 | $454K | Hold |
15,358
| – | – | 0.1% | 111 |
|
|
2014
Q3 | $431K | Buy |
15,358
+1,687
| +12% | +$47.3K | 0.1% | 108 |
|
|
2014
Q2 | $385K | Buy |
13,671
+206
| +2% | +$5.87K | 0.09% | 116 |
|
|
2014
Q1 | $410K | Sell |
13,465
-3,660
| -21% | -$109K | 0.1% | 108 |
|
|
2013
Q4 | $498K | Buy |
17,125
+362
| +2% | +$10.5K | 0.11% | 99 |
|
|
2013
Q3 | $457K | Sell |
16,763
-168
| -1% | -$4.57K | 0.11% | 101 |
|
|
2013
Q2 | $450K | Buy |
+16,931
| New | +$468K | 0.11% | 99 |
|
Other funds holding PFE
L. Roy Papp & Associates's PFE Position: Q2 2026 in Review
L. Roy Papp & Associates reduced its Pfizer (PFE) stake by 1.8% in Q2 2026, selling an estimated $6.28K and leaving 13,078 shares worth $315K. The position accounts for 0.03% of the portfolio, ranked #162.
L. Roy Papp & Associates first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.48M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- L. Roy Papp & Associates held 13,078 shares of Pfizer worth $315K as of Q2 2026.
- L. Roy Papp & Associates sold 240 Pfizer shares in Q2 2026, an estimated $6.28K.
- Pfizer made up 0.03% of L. Roy Papp & Associates's portfolio in Q2 2026, its #162 holding.
- L. Roy Papp & Associates first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- L. Roy Papp & Associates's Pfizer position peaked at $1.48M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on L. Roy Papp & Associates's 13F filing for Q2 2026, filed 23 Jul 2026.